一种新的口服糖尿病和肥胖药丸,或复方体,帮助成年人在18个月内损失23磅,并产生轻微副作用。 A new oral diabetes and obesity pill, orforglipron, helped adults lose up to 23 pounds in 18 months with mild side effects.

Eli Lilly开发的一种新的口服避孕药或口服短片帮助患有肥胖症和2型糖尿病的成年人在一项大型国际研究中,在18个月中丧失了体重的10%左右。 A new oral pill, orforglipron, developed by Eli Lilly, helped adults with obesity and type 2 diabetes lose about 10% of their body weight over 18 months in a large international study. 每天的药片不需要制冷或注射,其结果与Ozempic和Mounjaro等可注射的GLP-1药物类似,最高剂量导致平均体重减少23磅。 The daily pill, which does not require refrigeration or injections, showed results comparable to injectable GLP-1 drugs like Ozempic and Mounjaro, with the highest dose leading to an average 23-pound weight loss. 副作用是轻度到中度,主要是胃肠。 Side effects were mild to moderate, mainly gastrointestinal. 如果林业发展局于2026年批准,该药物可能更负担得起,更易于获取,特别是在肥胖症造成的死亡人数高于主要传染病的低收入国家。 If approved by the FDA in 2026, the drug could be more affordable and accessible, especially in low-income countries where obesity causes more deaths than major infectious diseases.